Latest Regulatory Progress News

ACDC Metals reports promising mineralogy results from its Goschen Central Project, highlighting valuable rare earth elements and heavy minerals. The company maintains a solid cash balance and advances its retention licence application, positioning itself well in the evolving rare earth sector.

Bio-Gene Technology Limited reports significant progress in Q1 FY26, unveiling new product opportunities and positive efficacy data, alongside securing US Department of Defense grants.

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW, secures $34 million through capital raising, and acquires promising US exploration assets, setting the stage for growth.

Orpheus Uranium has advanced its exploration agenda by finalizing multiple Native Title Mining Agreements across South Australia and the Northern Territory, while strategically acquiring the Oobagooma Project in Western Australia to diversify its uranium asset base.

Far East Gold reports a productive September quarter with significant drilling results at its Idenburg Project, including a new high-grade discovery at North Bermol and an expanded pipeline of exploration targets.

Echo IQ Limited has advanced its EchoSolv heart failure solution towards FDA submission, driven by a landmark clinical validation study and a sharp rise in US platform adoption. Strategic partnerships and international expansion efforts underscore the company’s growing footprint in cardiology AI.

Cobalt Blue Holdings advances its Kwinana Cobalt Refinery with a critical Works Approval and secures letters of intent covering 70% of initial production, while its Broken Hill Cobalt Project gains a three-year Major Project Status extension.

Bioxyne Limited has reported a record-breaking first quarter for FY26, with revenues soaring 210% year-on-year, driven by strong demand in cannabis products and strategic European market advances.

Magnetite Mines has made significant strides in developing its Razorback Iron Ore Project, securing $3.86 million in new funding and uncovering promising rare earth mineralisation at Ironback Hill. The company continues to navigate strategic partnerships and regulatory approvals to advance its long-life magnetite project.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.